Compare LMAT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | MESO |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2006 | N/A |
| Metric | LMAT | MESO |
|---|---|---|
| Price | $103.56 | $14.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $105.80 | N/A |
| AVG Volume (30 Days) | 250.9K | ★ 272.5K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $249,602,000.00 | N/A |
| Revenue This Year | $14.21 | $629.74 |
| Revenue Next Year | $8.88 | $30.65 |
| P/E Ratio | $152.37 | ★ N/A |
| Revenue Growth | ★ 13.53 | N/A |
| 52 Week Low | $79.40 | $12.66 |
| 52 Week High | $118.01 | $21.50 |
| Indicator | LMAT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 42.56 |
| Support Level | $95.41 | $13.82 |
| Resistance Level | $105.17 | $16.06 |
| Average True Range (ATR) | 3.58 | 0.61 |
| MACD | 0.21 | -0.29 |
| Stochastic Oscillator | 77.18 | 6.54 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.